Stromacel Stock Price, News & Analysis (OTCMKTS:PROT)

$0.01 0.00 (0.00 %)
(As of 02/25/2018 04:30 AM ET)
Previous Close$0.01
Today's Range$0.01 - $0.01
52-Week Range$0.01 - $0.10
Volume1,000 shs
Average Volume605 shs
Market Capitalization$79,110.00
P/E Ratio-0.10
Dividend YieldN/A

About Stromacel (OTCMKTS:PROT)

Stromacel Inc. is a biotechnology company. The Company is a subsidiary of Proteonomix Inc. It offers technology in the field of cellular medicine to international clients. The Company intends to conduct phased human studies of its cellular materials in application to the treatment of cardiac and other diseases.

Receive PROT News and Ratings via Email

Sign-up to receive the latest news and ratings for PROT and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A


Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A


Trailing P/E Ratio-0.1
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A


Trailing EPS($0.10)
Net IncomeN/A
Net MarginsN/A
Return on Equity3,244.33%
Return on Assets90.15%


Outstanding Shares7,910,000

Stromacel (OTCMKTS:PROT) Frequently Asked Questions

What is Stromacel's stock symbol?

Stromacel trades on the OTCMKTS under the ticker symbol "PROT."

Who are some of Stromacel's key competitors?

Who are Stromacel's key executives?

Stromacel's management team includes the folowing people:

  • Michael Cohen, Chairman of the Board, President, Chief Executive Officer, Chief Operating Officer (Age 47)
  • Thomas P. Monahan, Chief Financial Officer (Age 67)
  • Steven Byle, Chief Technical Officer, Director (Age 45)
  • Ian McNiece Ph.D., Vice President - Scientific Development , Chief Scientific Officer, Director (Age 58)
  • Roger L. Fidler, General Counsel, Treasurer, Director (Age 62)
  • Jason B. Isaacs, Corporate Secretary (Age 40)

How do I buy Stromacel stock?

Shares of Stromacel can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Stromacel's stock price today?

One share of Stromacel stock can currently be purchased for approximately $0.01.

How big of a company is Stromacel?

Stromacel has a market capitalization of $79,110.00.

How can I contact Stromacel?

Stromacel's mailing address is 187 Mill Ln, MOUNTAINSIDE, NJ 07092-2918, United States. The biotechnology company can be reached via phone at +1-973-5446116.

MarketBeat Community Rating for Stromacel (PROT)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  17 (Vote Outperform)
Underperform Votes:  19 (Vote Underperform)
Total Votes:  36
MarketBeat's community ratings are surveys of what our community members think about Stromacel and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Stromacel (OTCMKTS:PROT) Analyst Ratings History

No equities research coverage for this company has been tracked by MarketBeat


Earnings History for Stromacel (OTCMKTS:PROT)

No earnings announcements for this company have been tracked by


Stromacel (OTCMKTS:PROT) Earnings Estimates

No earnings estimates for this company have been tracked by


Dividend History for Stromacel (OTCMKTS:PROT)

No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Stromacel (OTCMKTS PROT)

No insider trades for this company have been tracked by


Stromacel (OTCMKTS PROT) News Headlines

No headlines for this company have been tracked by

SEC Filings

Stromacel (OTCMKTS:PROT) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media


Stromacel (OTCMKTS:PROT) Income Statement, Balance Sheet and Cash Flow Statement


Stromacel (OTCMKTS PROT) Stock Chart for Sunday, February, 25, 2018

Loading chart…

This page was last updated on 2/25/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.